Ingredient or product comparison
Bioavailability Comparison: Oral vs Subcutaneous vs Topical GHK-Cu
Delivery route determines whether a peptide reaches its target tissue at a concentration sufficient to produce measurable effects. Bioavailability varies dramatically across administration methods, and for GHK-Cu, the difference is not incremental. It's an ord
This source-based comparison does not add ratings or recommend a winner.
- Delivery route determines whether a peptide reaches its target tissue at a concentration sufficient to produce measurable effects. Bioavailability varies dramatically across administration methods, and for GHK-Cu, the difference is not incremental. It's an order of magnitude.
- Subcutaneous injection places GHK-Cu directly into the hypodermis, the layer of loose connective tissue beneath the dermis. From this depot, the peptide diffuses into capillary beds and enters systemic circulation without encountering gastric acid or hepatic first-pass metabolism. Subcutaneous bioavailability for small peptides typically ranges from 70% to 95%, depending on molecular weight, lipophilicity, and injection site vascularity. Because GHK-Cu is a small tripeptide (molecular weight 340 Da) with moderate hydrophilicity, it absorbs efficiently from subcutaneous tissue. Plasma concentration peaks within 30 to 90 minutes post-injection, and the peptide circulates in its intact form until renal filtration or enzymatic cleavage by circulating peptidases occurs.
- Topical application to intact skin delivers GHK-Cu directly to dermal tissue. The primary site of interest for collagen synthesis, wound healing, and extracellular matrix remodeling research. The stratum corneum, the outermost layer of the epidermis, is a lipid-rich barrier that restricts penetration of hydrophilic molecules. GHK-Cu, being a charged tripeptide with copper coordination, does not readily cross this barrier without formulation enhancement. Liposomal encapsulation, penetration enhancers (such as dimethyl sulfoxide or propylene glycol), and microneedling are strategies used to improve dermal delivery. When properly formulated, topical GHK-Cu achieves high local concentration in the dermis and epidermis. The exact tissues where fibroblast activity, collagen production, and matrix metalloproteinase regulation occur. Systemic absorption from topical application is minimal, which is advantageous for localized tissue studies but limits whole-body peptide exposure.
- Oral administration, as discussed, suffers from enzymatic degradation and first-pass hepatic clearance. After absorption from the intestine (assuming any intact peptide survives), the hepatic portal vein carries absorbed compounds directly to the liver before they reach systemic circulation. The liver expresses high levels of peptidases and metabolic enzymes that further degrade peptides. This hepatic first-pass effect is the reason many orally administered drugs have bioavailability far below 100%. And for unprotected peptides like GHK-Cu, the effect is severe. Even peptides that resist gastric digestion often undergo significant hepatic metabolism, reducing the amount of intact compound that reaches peripheral tissues.
- For research applications requiring measurable plasma levels of GHK-Cu, subcutaneous injection is the most reliable route. For dermatological or wound healing studies where the target tissue is skin, topical formulations designed for enhanced penetration provide high local concentration without systemic exposure variability. Oral administration is the least dependable route when intact peptide delivery is the experimental variable. If the research question involves downstream metabolites or the effect of constituent amino acids and copper ions, oral administration may be appropriate. But that is a fundamentally different study than one examining the bioactivity of the intact GHK-Cu tripeptide.